| abstract |
The present invention relates to a pharmaceutical composition comprising a physiologically active compound of formula (I) and a prodrug thereof, and a pharmaceutically acceptable salt and solvate of said compound and its prodrug, and a novel compound within the scope of formula (I) ≪ / RTI >n n n (I)n n n n n n n n Wherein R 1 is aryl or heteroaryl, R 2 is hydrogen, acyl, cyano, halo, or cyano, heteroaryl, heterocycloalkyl, -Z 1 R 8 , -C (═O) NY 3 Y 4, -CO 2 R 8, -NY 3 Y 4, -N (R 6) -C (= O) -R 7, -N (R 6) -C (= O) -NY 3 Y 4 , -N (R 6 ) -C (═O) -OR 7 , -N (R 6 ) -SO 2 -R 7 , -N (R 6 ) -SO 2 -NY 3 Y 4 and at least one halogen atom substituted by a substituent selected from the group or unsubstituted lower alkenyl, or lower alkyl; R 3 is hydrogen, aryl, cyano, halo, heteroaryl, lower alkyl, -C (= O) -OR 5, -C (= O) -NY 3 Y 4 , X 1 is N, CH 3, C-halo, C-CN, CR 7 , C-NY 3 Y 4 , C-OH, CZ 2 R 7 , -OR 5, CC (= O) -NY 3 Y 4, CN (R 8) -C (= O) -R 7, C-S0 2 -NY 3 Y 4, CN (R 8) -SO 2 -R 7, C- alkenyl, alkynyl, C- or C-NO 2 Im). n n n Such compounds and compositions have properties that can inhibit useful pharmaceutical properties, particularly protein kinases. |